C5 and arthritic joint disease: Our group and collaborators demonstrated the successful delivery of IL-4 in vivo using a synovium targeting peptide in the xenograft SCID mouse model, and the selective accumulation of an anti-C5 antibody fused to the same synovium targeting peptide in affected joints of rodent models of arthritis (37, 38).